Tempus xO Assay Validation



Tempus, a technology company focused on helping doctors personalize cancer care by collecting and integrating molecular and clinical data, today announced its Tempus xO assay has been validated with clinically actionable variance. The Tempus xO assay combines a 1,711 gene somatic and germline DNA sequencing panel with RNA-sequencing. It makes use of FFPE tumor samples and matched normal saliva or blood samples. The assay is designed to identify actionable oncologic variants in a wide array of solid tumor types and is capable of detecting both germline and somatic single nucleotide polymorphisms (SNPs), indels less than 100 bp, copy number variants, and gene rearrangements containing one or more RNA coding sequences.

“The Tempus xO test is a leader in the field of comprehensive genomic testing,” said Gary Palmer, Chief Medical Officer at Tempus. “The combination of genomic and clinical data at a more affordable price point makes Tempus xO unparalleled in the industry.”

CAP/CLIA validation of the Tempus xO panel has focused on actionable variants that are assayed with a variant allele fraction (VAF) of 5% or greater. Validation of Tempus xO resulted in a 98.3% sensitivity and 100% specificity for DNA-derived clinically actionable variants. These results establish high sensitivity and specificity for the Tempus xO assay.

The xO assay is used across a diverse set of clinical settings including leading academic centers, NCI designated cancer centers, hospital networks and community hospitals.

About Tempus

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. We enable physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform. We provide genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data. For more information, visit tempus.com.